Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$100.1MCash, Jun 2026
18moCash Runway (est.)
+16%Share Count, 1 Year
Follow OCGN by emailGet an email when OCGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OCGN, unsubscribe in one click. Privacy
📣 What OCGN Says Is Next
1Q 2027 · “Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.”
Company press release, Jul 13, 2026 · SEC filing
by 2028 · “"With our anticipated cash runway extended into 2028, we are well-positioned to advance three late-stage programs and execute toward our goal of filing three BLAs by 2028, bringing potentially transformative therapies to patients who have long awaited meaningful treatment options." About Ocugen, Inc .”
Company press release, May 14, 2026 · SEC filing
mid-2027 · “Plan to submit the BLA for OCU410ST by mid-2027.”
Company press release, May 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
OCGN reported $100.1M in cash and short-term investments (as of Jun 30, 2026) and used about $17.1M/quarter in operations, an estimated runway of 17.5 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.